PremiumRatingsArcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating Arcellx reports FY24 EPS ($2.00), consensus ($1.50) PremiumThe FlyArcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole Arcellx price target raised to $115 from $73 at Barclays Arcellx, Inc. Reports Q3 2024 Earnings Highlights PremiumThe FlyArcellx price target raised to $106 from $77 at Baird Arcellx price target raised to $106 from $81 at Morgan Stanley Arcellx price target raised to $100 from $84 at BofA 
